A global atlas of genetic associations of 220 deep phenotypes - Sakaue, Saori; Kanai, Masahiro; Tanigawa, Yosuke; Karjalainen, Juha; Kurki, Mitja; Koshiba, Seizo; Narita, Akira; Konuma, Takahiro; Yamamoto, Kenichi; Akiyama, Masato; Ishigaki, Kazuyoshi; Suzuki, Akari; et al. (medRxiv, 2020)
The current genome-wide association studies (GWASs) do not yet capture sufficient diversity in terms of populations and scope of phenotypes. To address an essential need to expand an atlas of genetic associations in non-European populations, we conducted 220 deep-phenotype GWASs (disease endpoints, biomarkers, and medication usage) in BioBank Japan (n = 179,000), by incorporating past medical history and text-mining results of electronic medical records. Meta-analyses with the harmonized phenotypes in the UK Biobank and FinnGen (ntotal = 628,000) identified over 4,000 novel loci, which substantially deepened the resolution of the genomic map of human traits, benefited from East Asian endemic diseases and East Asian specific variants. This atlas elucidated the globally shared landscape of pleiotropy as represented by the MHC locus, where we conducted fine-mapping by HLA imputation. Finally, to intensify the value of deep-phenotype GWASs, we performed statistical decomposition of matrices of phenome-wide summary statistics, and identified the latent genetic components, which pinpointed the responsible variants and shared biological mechanisms underlying current disease classifications across populations. The decomposed components enabled genetically informed subtyping of similar diseases (e.g., allergic diseases). Our study suggests a potential avenue for hypothesis-free re-investigation of human disease classifications through genetics.Competing Interest StatementM.A.R. is on the SAB of 54Gene and Computational Advisory Board for Goldfinch Bio and has advised BioMarin, Third Rock Ventures, MazeTx and Related Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Funding StatementThis research was supported by the Tailor-Made Medical Treatment program (the BioBank Japan Project) of the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), the Japan Agency for Medical Research and Development (AMED). The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and nine industry partners (AbbVie, AstraZeneca, Biogen, Celgene, Genentech, GSK, MSD, Pfizer and Sanofi). Following biobanks are acknowledged for collecting the FinnGen project samples: Auria Biobank (https://www.auria.fi/biopankki/), THL Biobank (https://thl.fi/fi/web/thl-biopank), Helsinki Biobank (https://www.terveyskyla.fi/helsinginbiopankki/), Northern Finland Biobank Borealis (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki), Finnish Clinical Biobank Tampere (https://www.tays.fi/biopankki), Biobank of Eastern Finland (https://ita-suomenbiopankki.fi), Central Finland Biobank (https://www.ksshp.fi/fi-FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank (https://www.bloodservice.fi/Research%20Projects/biobanking), Terveystalo Biobank Finland (https://www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/). S.S. was in part supported by The Mochida Memorial Foundation for Medical and Pharmaceutical Research. M.Kanai was supported by a Nakajima Foundation Fellowship and the Masason Foundation. Y.Tanigawa is in part supported by a Funai Overseas Scholarship from the Funai Foundation for Information Technology and the Stanford University School of Medicine. M.A.R. is in part supported by National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) under award R01HG010140 (M.A.R.), and a National Institute of Health center for Multi- and Trans-ethnic Mapping of Mendelian and Complex Diseases grant (5U01 HG009080). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Y.O. was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI (19H01021, 20K21834), and AMED (JP20km0405211, JP20ek0109413, JP20ek0410075, JP20gm4010006, and JP20km0405217), Takeda Science Foundation, and Bioinformatics Initiative of Osaka University Graduate School of Medicine, Osaka University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All the participants provided written informed consent approved from ethics committees of the Institute of Medical Sciences, the University of Tokyo and RIKEN Center for Integrative Medical Sciences.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe genotype data of BBJ used in this study are available from the Japanese Genotype-phenotype Archive (JGA; http://trace.ddbj.nig.ac.jp/jga/index_e.html) with accession code JGAD00000000123 and JGAS00000000114. The UKB analysis was conducted via application number 47821. This study used the FinnGen release 3 data. Summary statistics of BBJ GWAS and trans-ethnic meta-analysis will be publicly available without any restrictions. http://trace.ddbj.nig.ac.jp/jga/index_e.html